Search Results 411-420 of 14952 for alt

1. A study of how current treatments impact the course of relapsed myeloma and the effect of the treatments on the quality-of-life measurements. - Mayo Clinic

   Alanine aminotransferase (ALT) < 2.5 x ULN;; Adequate renal function;; Creatinine clearance > 30 mL/min (according to the Cockcroft Gault formula, by 24-hour ...

2. A Study to Evaluate the Effect of 1,25-Dihydroxyvitamin D3 to Treat Insulin Secretion and Muscle Strength in Pre-diabetics - Mayo Clinic

   Chronic active liver disease (bilirubin > 1.2 mg/dL, AST > 144 IU/L, or ALT > 165 IU/L). History of chronic hepatitis. History of depression, anxiety or ...

3. A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) - Mayo Clinic

   ... ALT < 3 × ULN that are not attributable to HBV infection), and are willing to start and maintain antiviral treatment for the duration of the study, are allowed.

4. Open-Label extension study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis - Mayo Clinic

   ALT or AST > 250 U/L x ULN; ALP > 10 × ULN. Participation in another interventional clinical study and receipt of any other investigational medication or ...

5. (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive - Mayo Clinic

   Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤2.5×ULN. Exclusion Criteria: Acute Promyelocytic Leukemia (AML subtype M3). AML ...

6. Escalating Dose Study in Subjects with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia - Mayo Clinic

   AST and ALT ≤ 3 × ULN; Platelet count ≥ 50,000/µL (non-hodgkin & Waldenstrom's); Platelet count ≥ 30,000/µL (chronic lymphocytic leukemia); Absolute ...

7. Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents - Mayo Clinic

   AST (SGOT) and ALT (SGPT) ≤ 3 x ULN. Patient must be disease free of prior malignancies for at least 5 years with exception of currently treated basal cell ...

8. Bendamustine Hydrochloride and Rituximab with or without Bortezomib Followed by Rituximab with or without Lenalidomide in Treating Patients with High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma - Mayo Clinic

   AST and ALT ≤ 5 x upper limit of normal (ULN); Alkaline phosphatase ≤ 5 x ULN; Total bilirubin ≤ 1.5 x ULN (patients with known Gilbert disease should ...

9. Venetoclax And Vincristine Liposomal In Treating Patients With Relapsed Or Refractory T-cell Or B-cell Acute Lymphoblastic Leukemia - Mayo Clinic

   Adequate liver function with AST/ALT less than 3 X upper limit of normal and total bilirubin less than 2 mg/dL within 7 days prior to first dose of study agent.

10. Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma - Mayo Clinic

    Patients must have adequate liver function as defined by total bilirubin of ≤ 1.5 mg/dl and ALT or AST < 2.5 times the institution's upper normal limit.